Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Journal of Clinical Oncology

• Publication date

  1989-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1989.7.6.710PMID 2715802
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line.

  1987cited by this paper
• Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial.

  1987cited by this paper
• Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.

  1986cited by this paper
• Anatagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro

  1985cited by this paper
• Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/calcium-dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary.

  1985cited by this paper
• Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro.

  1985cited by this paper
• Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro.

  1985cited by this paper
• Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues.

  1984cited by this paper
• Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase.

  1984cited by this paper
• A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization.

  1984cited by this paper
• Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.

  1984cited by this paper
• Tamoxifen and 5-fluorouracil in breast cancer: modulation of cellular RNA.

  1983cited by this paper
• Efforts to combine endocrine and chemotherapy in the management of breast cancer: Do two and two equal three?

  1983cited by this paper
• Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase.

  1983cited by this paper
• Tamoxifen and 5-fluorouracil in breast cancer: cytotoxic synergism in vitro.

  1983cited by this paper
• Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells.

  1983cited by this paper
• Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture.

  1978cited by this paper
• The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.

  1975cited by this paper
• Synergistic interaction of anticancer agents: a cellular perspective.

  1975cited by this paper

• Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer.

  2026cites this paper
• Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial

  2025cites this paper
• Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens

  2025cites this paper
• Sequential Diagnosis of Metastatic Breast Cancer and Follicular Lymphoma in a Postmenopausal Woman: Navigating Endocrine and Cytotoxic Therapies in a Complex Oncologic Setting

  2025cites this paper
• Three-dimensional analysis of mitochondria in a patient-derived xenograft model of triple negative breast cancer reveals mitochondrial network remodeling following chemotherapy treatments

  2024cites this paper
• Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial

  2024cites this paper
• Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

  2023cites this paper
• Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18F-FES PET

  2022cites this paper
• Independent Drug Action in Combination Therapy: Implications for Precision Oncology

  2022cites this paper
• Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go???

  2022cites this paper
• Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer

  2022cites this paper
• Selective Estrogen Receptor Modulators (SERMs) Synergize with Cisplatin, Induce Apoptosis and Suppress Cellular Migration and Colony Formation of Lung Cancer Cells.

  2021cites this paper
• Recent advances in neoadjuvant therapy for breast cancer

  2021cites this paper
• Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• Radiosensitivity: Gender and Order of Administration of G-CSF, An Experimental Study in Mice

  2019cites this paper
• Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?

  2019cites this paper
• Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer (CBCSG‐036): A randomized, controlled, multicenter trial

  2019cites this paper
• Combination of Aromatase Inhibitors with Metronomic Capecitabine: A New Chemoendocrine Treatment for Advanced Breast Cancer

  2019cites this paper
• ALK inhibitors and cranial radiotherapy in brain metastasis from NSCLC

  2018influential citation
• How to Design Phase I Trials in Oncology

  2018cites this paper
• Methods and Biostatistics in Oncology

  2018cites this paper
• Suppressive drug combinations and their potential to combat antibiotic resistance

  2017cites this paper
• Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

  2017cites this paper
• Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.

  2017cites this paper
• Endocrine Therapies in the Adjuvant and Advanced Disease Settings

  2017cites this paper
• Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies

  2017cites this paper
• Approaches to modernize the combination drug development paradigm

  2016cites this paper
• Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells.

  2016cites this paper
• Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features

  2016cites this paper
• Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer : NACED-Randomized Multicenter Phase II Trial

  2015cites this paper
• Neoadjuvant Chemotherapy with or without Concurrent Hormone Therapy in Estrogen Receptor-Positive Breast Cancer: NACED-Randomized Multicenter Phase II Trial.

  2015cites this paper
• Tamoxifen Prevents Apoptosis and Follicle Loss from Cyclophosphamide in Cultured Rat Ovaries1

  2015cites this paper
• Challenges and Potential for Ovarian Preservation with SERMs1

  2015cites this paper
• Moleküler Hedefli Anti-Kanser Ajan Kombinasyonlarini Optimize Etmek İçin Stratejiler Strategies to Optimize the Molecularly Targeted Anti-Cancer Agent Combinations

  2015cites this paper
• Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

  2014cites this paper
• Ovarian function preservation with GnRH agonist in young breast cancer patients: does it impede the effect of adjuvant chemotherapy?

  2014cites this paper
• First-LineTreatmentPatternsandClinicalOutcomes inPatientsWith HER 2-PositiveandHormoneReceptor-PositiveMetastaticBreast Cancer

  2013cites this paper
• First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.

  2013cites this paper
• Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials

  2013cites this paper
• First-LineTreatmentPatternsandClinicalOutcomesinPatientsWith HER2-PositiveandHormoneReceptor-PositiveMetastaticBreast CancerFromregistHER

  2013cites this paper
• The aromatase inhibitor letrozole enhances the effect of doxorubicin and docetaxel in an MCF7 cell line model

  2012cites this paper
• Management of castration‐resistant prostate cancer: a call to urologists

  2012cites this paper
• Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.

  2012cites this paper
• Simultaneous Letrozole Letrozole Letrozole + doxorubicin Letrozole + doxorubicin Letrozole + docetaxel Letrozole + docetaxel Letrozole + doxorubicin + docetaxel Letrozole + doxorubicin + docetaxel Sequential Letrozole Letrozole Letrozole Doxorubicin Letrozole Docetaxel Letrozole Doxorubicin + doceta

  2012cites this paper
• The role of estrogen and estrogen receptors in chemoresistance.

  2011cites this paper
• Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.

  2011cites this paper
• Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.

  2011cites this paper
• Roles and Mechanisms of Estrogen and Estrogen Receptors in Breast Cancer Resistant to Chemotherapy

  2011cites this paper
• Tamoxifen for breast cancer.

  2010cites this paper
• Combining and Sequencing Adjuvant Chemotherapy and Tamoxifen in Postmenopausal Women with Node-Positive Breast Cancer

  2010cites this paper
• Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer

  2009cites this paper
• The marriage of growth factor inhibitors and chemotherapy: bliss or bust?

  2009cites this paper
• Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.

  2009cites this paper
• Timing of adjuvant therapy.

  2009cites this paper
• Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.

  2008cites this paper
• The concept of mathematically optimised dose-scheduling as applied to the adjuvant chemotherapy of primary breast cancer: theory and recent results

  2008cites this paper
• Enhancing Hormonal Therapy for Breast Cancer by Combination with a Well-Known Approved Pharmaceutical with Little Toxicity

  2008cites this paper
• Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference.

  2007cites this paper
• Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells

  2007cites this paper
• Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells

  2007cites this paper
• Evaluation of the Effect of Paclitaxel, Epirubicin and Tamoxifen by Cell Kinetics Parameters in Estrogen-Receptor-Positive Ehrlich Ascites Tumor (Eat) Cells Growing in vitro

  2007cites this paper
• Evaluation of the effect of paclitaxel, epirubicin and tamoxifen by cell kinetics parameters in estrogen-receptor-positive ehrlich ascites tumor (eat) cells growing in vitro.

  2007cites this paper
• Strategies for optimizing combinations of molecularly targeted anticancer agents

  2006cites this paper
• Targeting insulin-like growth factor pathways

  2006cites this paper
• Endocrine Therapy of Breast Cancer

  2006cites this paper
• Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.

  2006cites this paper
• Evidence-Based Management of Breast Cancer

  2006cites this paper
• Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.

  2005cites this paper
• The effects of epirubicin and tamoxifen on 3 H- thymidine labelling index in estrogen - receptor - positive Ehrlich ascites tumor cells growing in vivo

  2005cites this paper
• Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

  2005cites this paper
• Combined effects of epirubicin and tamoxifen on the cell-cycle phases in estrogen-receptor-negative Ehrlich ascites tumor cells

  2005cites this paper
• Adjuvant endocrine therapy.

  2004cites this paper
• Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study.

  2004cites this paper
• Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer.

  2003cites this paper
• Tailoring adjuvant treatments for the individual breast cancer patient.

  2003cites this paper
• Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.

  2003cites this paper
• Adjuvant Treatment in Node-Negative, Postmenopausal Breast Cancer

  2001cites this paper
• Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients

  1999cites this paper
• Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial.

  1999cites this paper
• Adjuvant therapy of breast cancer: update.

  1999cites this paper
• Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro

  1998cites this paper
• [No advantage to using the CMF-regimen for node positive, postmenopausal, receptor-positive mammary carcinoma with adjuvant tamoxifen therapy].

  1998cites this paper
• Kein vorteil durch zusätzliche CMF-Behandlung bei nodal positivem, postmenopausalem, Rezeptor-positivem Mammakarzinom unter adjuvanter Tamoxifen-Therapie

  1998cites this paper
• Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status

  1998cites this paper
• Controversial issues in adjuvant systemic therapy of early breast cancer.

  1998cites this paper
• An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer

  1997cites this paper
• Should adjuvant chemotherapy be used to treat breast cancer in elderly patients (> or = 70 years of age)?

  1997cites this paper
• Application of neoadjuvant chemoendocrine therapy for operable breast carcinomas.

  1997cites this paper
• The effects of postradiation treatment with tamoxifen on local control and cosmetic outcome in the conservatively treated breast

  1997cites this paper
• Steroid hormone receptors and antineoplastic chemotherapy in human breast cancer.

  1997cites this paper
• Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group.

  1997cites this paper
• Systemic Treatment Approaches in Breast Cancer

  1997cites this paper
• Selective primary systemic treatment for operable breast cancer : a randomised trial

  1997cites this paper
• Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer.

  1996cites this paper
• Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro.

  1996cites this paper
• A propos de deux essais thérapeutiques contrôlés récemment publiés de chimiothérapie d'induction dans les carcinomes du nasopharynx et du sinus piriforme.

  1996cites this paper
• Adjuvant Therapy of Breast Cancer V

  1996cites this paper
• Adjuvant systemic therapy: the issues of timing and sequence.

  1996cites this paper
• Chimiothérapie première des cancers du sein

  1995cites this paper
• Adjuvant chemoendocrine therapy for early breast-cancer - is it worthwhile - (review).

  1995cites this paper